BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors

BioTheryX plans to continue building out Board of Directors with key biopharma industry leaders as Company transitions from preclinical to clinical stage with lead Acute Myeloid Leukemia ("AML") compound BTX-A51 CHAPPAQUA, N.Y., Sept. 18, 2019... Biopharmaceuticals, Oncology, Personnel BioTheryX, Protein Homeostatic Modulators
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news